Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Working Capital Changes (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Other Working Capital Changes over the past 16 years, most recently at -$1.6 million for Q2 2025.

  • Quarterly results put Other Working Capital Changes at -$1.6 million for Q2 2025, down 85.52% from a year ago — trailing twelve months through May 2025 was -$378000.0 (up 86.76% YoY), and the annual figure for FY2025 was -$378000.0, up 86.76%.
  • Other Working Capital Changes for Q2 2025 was -$1.6 million at Lifecore Biomedical, Inc. \De\, down from $97000.0 in the prior quarter.
  • Over the last five years, Other Working Capital Changes for LFCR hit a ceiling of $2.6 million in Q3 2021 and a floor of -$6.6 million in Q2 2021.
  • Median Other Working Capital Changes over the past 5 years was $12500.0 (2022), compared with a mean of -$634888.9.
  • Biggest five-year swings in Other Working Capital Changes: skyrocketed 1981.6% in 2021 and later crashed 31678.57% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Other Working Capital Changes stood at -$2.6 million in 2021, then skyrocketed by 99.46% to -$14000.0 in 2022, then crashed by 31678.57% to -$4.4 million in 2023, then skyrocketed by 120.79% to $925000.0 in 2024, then plummeted by 274.49% to -$1.6 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$1.6 million (Q2 2025), $97000.0 (Q1 2025), and $925000.0 (Q4 2024) per Business Quant data.